[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Based on the clinical presentation, severe immunosuppression (CD4 count 90), characteristic MRI findings (solitary, weakly ring-enhancing lesion in the corpus callosum), and the positive Epstein-Barr virus DNA in the cerebrospinal fluid, the most likely diagnosis is Primary CNS Lymphoma. This presentation is classic for PCNSL in advanced HIV disease.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "The medication that acts on the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide. It belongs to the class of fusion inhibitors.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Based on the presentation of recent onset symptoms like fever, malaise, diarrhea, and lymphadenopathy (consistent with Acute Retroviral Syndrome or ARS), coupled with a positive HIV test, the patient is most likely currently in the **acute (or primary)** stage of HIV infection. The CD4 count of 650/mm3 is above the threshold for AIDS, which further supports an earlier stage of infection rather than advanced disease.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "Based on the clinical presentation, laboratory findings (low CD4 count), imaging (cavitary lesions), and the identification of partially acid-fast gram-positive branching rods in the bronchoalveolar lavage, the most likely diagnosis is pulmonary nocardiosis.\n\nThe most appropriate drug for managing this condition is typically trimethoprim-sulfamethoxazole (TMP-SMX).\n\nThe mechanism of action of TMP-SMX involves the inhibition of folic acid synthesis in bacteria.\n*   Sulfamethoxazole inhibits dihydropteroate synthase, blocking the incorporation of para-aminobenzoic acid (PABA) into folic acid.\n*   Trimethoprim inhibits dihydrofolate reductase (DHFR), blocking the reduction of dihydrofolic acid to tetrahydrofolic acid.\n\nBy inhibiting sequential steps in the same metabolic pathway (folic acid synthesis), the combination is synergistic and often bactericidal.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "Thank you for your question.\n\nThe question asks about the target of antibodies generated during natural HIV infection, specifically against the HIV envelope proteins, which are also targets for diagnostic tests. The physician scientist is looking to develop a new, potent antibody against the *same* targets.\n\nThe HIV envelope consists of two main glycoproteins:\n1.  **gp120:** The outer surface protein responsible for binding to the CD4 receptor and co-receptors (like CCR5 or CXCR4) on host cells.\n2.  **gp41:** The transmembrane protein that anchors gp120 to the viral membrane and mediates fusion between the viral and cell membranes after binding.\n\nBoth gp120 and gp41 are highly immunogenic and are the primary targets of antibodies produced during natural infection. These are the proteins detected by assays like ELISA and Western Blot.\n\nTherefore, the most likely target for the antibody the physician scientist is designing would be either **gp120** or **gp41**.\n\nSince the list of possible protein targets was not provided in your question, I cannot select from the options. However, based on the information given, the target would be one of these two major envelope proteins.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "Based on the biopsy finding of septate hyphae branching at acute angles, the most likely causal organism is **Aspergillus species**. This morphology is characteristic of *Aspergillus*.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Adding valganciclovir to zidovudine, lamivudine, and dolutegravir puts the patient at greatest risk for **myelosuppression**, specifically **neutropenia**, due to the combination of valganciclovir and zidovudine.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "That is an important question. While the mother's HIV antibody test is positive, that test is not useful for diagnosing HIV in the baby.\n\nMaternal HIV antibodies cross the placenta and will be present in the baby's blood for many months, even if the baby is not infected.\n\nThe most appropriate test to determine if the baby has HIV infection would be a **nucleic acid amplification test (NAAT)**, such as an **HIV RNA PCR (viral load test)** or an **HIV DNA PCR**. These tests directly detect the virus itself, not just antibodies, and are used to diagnose HIV in infants exposed to the virus. Antibody tests are not used for diagnosis in exposed infants under 18 months of age.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "After confirming the diagnosis and delivering the results, the most appropriate next step is to **counsel the patient extensively on the importance of disclosing his HIV status to his wife due to the risk of transmission and the public health implications**. The physician should strongly encourage the patient to inform his wife and offer support or resources to facilitate this disclosure.\n\nWhile maintaining patient confidentiality is paramount, the physician also has ethical and potentially legal duties regarding the prevention of HIV transmission to identifiable third parties, especially a spouse who is also a patient. Public health laws often mandate reporting of HIV cases, and public health departments can assist with partner notification if the patient is unwilling or unable to do so himself. Direct disclosure by the physician to the wife without the husband's consent is a complex ethical and legal issue and is generally considered a last resort after all attempts to encourage patient-led or facilitated disclosure have failed and specific criteria (which vary by jurisdiction) are met. Initial focus must be on patient counseling and encouraging voluntary disclosure.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Based on the clinical presentation, elevated serum amylase and lipase, and CT findings of edematous pancreatitis, this patient has acute pancreatitis.\n\nConsidering her medical history and reported information:\n\n1.  **Medications:** Certain HIV medications, particularly older nucleoside reverse transcriptase inhibitors (NRTIs) like didanosine (ddI) or stavudine (d4T), are known to cause pancreatitis. While less common with current standard regimens, this is a significant possibility, especially since her specific HIV medications are not identified. Metformin is not typically associated with pancreatitis.\n2.  **Gallstones:** The CT scan showed a normal gallbladder, making gallstone pancreatitis less likely in this case, although not impossible without further imaging.\n3.  **Alcohol:** She reports moderate social alcohol use, which is a potential but less likely cause than heavy or binge drinking.\n4.  **Other causes:** Hypertriglyceridemia, infections, and other less common etiologies are also possibilities that would need further evaluation.\n\nGiven her recent HIV diagnosis and unspecified HIV medication regimen, **drug-induced pancreatitis (specifically due to her HIV medications)** is the most likely etiology to consider strongly in this context, alongside other common causes like gallstones (despite the CT finding) and alcohol. Further investigation into her specific HIV regimen is crucial.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI). Its action mechanism disrupts the biological process of **reverse transcription**.\n\nHIV uses reverse transcriptase to convert its RNA genome into DNA. Zidovudine, once activated, inhibits this enzyme and causes chain termination, preventing the synthesis of viral DNA.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "Yes, there are known differences in DNA methylation profiles between active and latent HIV infection.\n\n1.  **Latent HIV:** The latent reservoir is characterized by silenced viral expression. DNA methylation, particularly around the HIV-1 Long Terminal Repeat (LTR), is one of the key epigenetic modifications contributing to this silencing, helping to maintain latency. There are also differences in methylation patterns of host genes in latently infected cells.\n2.  **Active HIV:** During active replication, viral gene expression is ongoing. The HIV LTR is less methylated compared to the latent state. Host cell DNA methylation patterns are also influenced by the active infection, inflammation, and immune activation, differing from those found in individuals on suppressive ART with a latent reservoir.\n\nSo, differences exist in both viral DNA methylation (especially the LTR) and host cell DNA methylation patterns between these two states.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]